Compugen Ltd.
NASDAQ:CGENBiotechnology
+$0.01 today
- Market cap
- $185.66M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
Volume 0.15M
Average 0.48M
CGEN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Compugen Ltd.NASDAQ: CGEN
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation of $0 in Q4 FY2025
Q4 FY2025 stock-based compensation was $0. Trailing-twelve-month stock-based compensation was $0.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 10.8 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 3.02M | -14.8% |
| FY2023 | 2023-12-31 | 3.55M | -18.0% |
| FY2022 | 2022-12-31 | 4.33M | +1.2% |
| FY2021 | 2021-12-31 | 4.28M | — |
Stock-Based Compensation vs competitors
How CGEN compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Stock-based compensation amounts to 0.0% of revenue for CGEN, versus a peer median of 210.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7M USD | +76.4% | -18.0% | 39.9% | |
| LTM Mar 2026 | $6.67M USD | -45.2% | -9.2% | 210.3% | |
| LTM Mar 2026 | $6.49M USD | -5.6% | +3.2% | — | |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| FY2025 | €4.26M EUR | +7.9% | +0.1% | 152.7% | |
| LTM Mar 2026 | $4.25M USD | -13.9% | -7.5% | — | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CGEN) | — | +1.9% | -5.4% | 210.3% | |
Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.2M) | (33.69M) | (18.75M) | (14.23M) | 35.34M |
| Depreciation & Amortization | 461K | 482K | 476K | 486K | 475K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.28M | 4.33M | 3.55M | 3.02M | 0 |
| Change in Working Capital | 6.82M | (5.55M) | (20.71M) | 62.05M | (5.35M) |
| Accounts Receivables | 2M | 3.04M | (61.11M) | 59.93M | 360K |
| Inventory | (3.37M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.37M | (1.6M) | 3.51M | (4.41M) | 517K |
| Other Working Capital | 3.79M | (7M) | 36.9M | 6.53M | (6.23M) |
| Other Non-Cash Items | (573K) | 515K | (452K) | (1.72M) | 1.16M |
| Operating Cash Flow | (22.75M) | (34.51M) | (35.89M) | 49.6M | 31.63M |
| Capital Expenditures | (292K) | (487K) | (172K) | (118K) | (306K) |
| Acquisitions (Net) | 3K | 2K | 0 | 0 | 1K |
| Purchases of Investments | (129.95M) | (76.9M) | (53.71M) | (159.75M) | (96.07M) |
| Sales of Investments | 136.85M | 114.45M | 89.39M | 113.95M | 126.37M |
| Other Investing Activities | 0 | 0 | 0 | (329K) | 0 |
| Investing Cash Flow | 6.62M | 37.06M | 35.51M | (46.25M) | 30M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 14.96M | 353K | 3.08M | 544K | 10.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.88M | 0 | 0 | 10K | (4K) |
| Financing Cash Flow | 16.84M | 353K | 3.08M | 554K | 10.6M |
| Effect of Forex Changes | 469K | (584K) | 129K | 68K | 135K |
| Net Change in Cash | 704K | 2.91M | 2.83M | 3.97M | 72.37M |
| Free Cash Flow | (23.04M) | (34.99M) | (36.06M) | 49.49M | 31.33M |
Compugen Ltd.
NASDAQ:CGEN
Intrinsic Alpha fair value
Locked
Current Price
$1.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.